Products

Therapeutic Protein/Peptide Component:

Indication(s): 

Owner

Key Attributes:

Development Status:

• Sustained glucagon levels for 8-10 hr post-dose (minimal peak levels)
• Consistent elevation of glucose for 8-10 hr post-dose (during fasting)
• Safety profile expected to be comparable to approved product
• Stable liquid small volume injection (27-30 G needle) administered with autoinjector

• Preclinical studies completed in rats, dogs, and monkeys
• Pharmacokinetics in rats, dogs and monkeys
• Proof of concept efficacy in fasting dog model
• Non-GLP single dose toxicology in rats